Selected research
Industry Research
Preclinical Pharmacokinetics Services Industry Research Report 2026
Market perspective
The global Preclinical Pharmacokinetics Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Preclinical Pharmacokinetics Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Preclinical Pharmacokinetics Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Preclinical Pharmacokinetics Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Preclinical Pharmacokinetics Services include Porsolt, Altasciences, Biocytogen, Charles River Laboratories, WuXi AppTec, PyschoGenics, Evotec (Cyprotex), QPS and Aurigene Pharmaceutical Services, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Preclinical Pharmacokinetics Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Preclinical Pharmacokinetics Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Preclinical Pharmacokinetics Services Market by Company
Porsolt
Altasciences
Biocytogen
Charles River Laboratories
WuXi AppTec
PyschoGenics
Evotec (Cyprotex)
QPS
Aurigene Pharmaceutical Services
Frontage Laboratories
Dalriada
Sygnature Discovery
Admescope
Imavita
IQVIA Laboratories
Pharmaron
Preclinical Pharmacokinetics Services Segment by Type
LC-MS/MS-Based Preclinical Pharmacokinetics Service
Immunoassay-Based Preclinical Pharmacokinetics Service
Others
Preclinical Pharmacokinetics Services Segment by Application
Innovative Small Molecule Drugs
Biopharmaceuticals
Traditional Chinese Medicine & Natural Products
Others
Preclinical Pharmacokinetics Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Pharmacokinetics Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preclinical Pharmacokinetics Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Pharmacokinetics Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Preclinical Pharmacokinetics Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- LC-MS/MS-Based Preclinical Pharmacokinetics Service
- Immunoassay-Based Preclinical Pharmacokinetics Service
- Others
Applications
- Innovative Small Molecule Drugs
- Biopharmaceuticals
- Traditional Chinese Medicine & Natural Products
- Others
Companies covered
- Porsolt
- Altasciences
- Biocytogen
- Charles River Laboratories
- WuXi AppTec
- PyschoGenics
- Evotec (Cyprotex)
- QPS
- Aurigene Pharmaceutical Services
- Frontage Laboratories
- Dalriada
- Sygnature Discovery
- Admescope
- Imavita
- IQVIA Laboratories
- Pharmaron
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Preclinical Pharmacokinetics Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 LC-MS/MS-Based Preclinical Pharmacokinetics Service
- 2.2.3 Immunoassay-Based Preclinical Pharmacokinetics Service
- 2.2.4 Others
- 2.3 Preclinical Pharmacokinetics Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Innovative Small Molecule Drugs
- 2.3.3 Biopharmaceuticals
- 2.3.4 Traditional Chinese Medicine & Natural Products
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Preclinical Pharmacokinetics Services Breakdown Data by Type
- 3.1 Global Preclinical Pharmacokinetics Services Historic Market Size by Type (2021-2026)
- 3.2 Global Preclinical Pharmacokinetics Services Forecasted Market Size by Type (2027-2032)
4 Preclinical Pharmacokinetics Services Breakdown Data by Application
- 4.1 Global Preclinical Pharmacokinetics Services Historic Market Size by Application (2021-2026)
- 4.2 Global Preclinical Pharmacokinetics Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Preclinical Pharmacokinetics Services Market Perspective (2021-2032)
- 5.2 Global Preclinical Pharmacokinetics Services Growth Trends by Region
- 5.2.1 Global Preclinical Pharmacokinetics Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Preclinical Pharmacokinetics Services Historic Market Size by Region (2021-2026)
- 5.2.3 Preclinical Pharmacokinetics Services Forecasted Market Size by Region (2027-2032)
- 5.3 Preclinical Pharmacokinetics Services Market Dynamics
- 5.3.1 Preclinical Pharmacokinetics Services Industry Trends
- 5.3.2 Preclinical Pharmacokinetics Services Market Drivers
- 5.3.3 Preclinical Pharmacokinetics Services Market Challenges
- 5.3.4 Preclinical Pharmacokinetics Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Preclinical Pharmacokinetics Services Players by Revenue
- 6.1.1 Global Top Preclinical Pharmacokinetics Services Players by Revenue (2021-2026)
- 6.1.2 Global Preclinical Pharmacokinetics Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Preclinical Pharmacokinetics Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Preclinical Pharmacokinetics Services Head Office and Area Served
- 6.4 Global Preclinical Pharmacokinetics Services Players, Product Type & Application
- 6.5 Global Preclinical Pharmacokinetics Services Manufacturers Established Date
- 6.6 Global Preclinical Pharmacokinetics Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Preclinical Pharmacokinetics Services Market Size (2021-2032)
- 7.2 North America Preclinical Pharmacokinetics Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Preclinical Pharmacokinetics Services Market Size by Country (2021-2026)
- 7.4 North America Preclinical Pharmacokinetics Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Preclinical Pharmacokinetics Services Market Size (2021-2032)
- 8.2 Europe Preclinical Pharmacokinetics Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Preclinical Pharmacokinetics Services Market Size by Country (2021-2026)
- 8.4 Europe Preclinical Pharmacokinetics Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Preclinical Pharmacokinetics Services Market Size (2021-2032)
- 9.2 Asia-Pacific Preclinical Pharmacokinetics Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Preclinical Pharmacokinetics Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Preclinical Pharmacokinetics Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Preclinical Pharmacokinetics Services Market Size (2021-2032)
- 10.2 South America Preclinical Pharmacokinetics Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Preclinical Pharmacokinetics Services Market Size by Country (2021-2026)
- 10.4 South America Preclinical Pharmacokinetics Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Preclinical Pharmacokinetics Services Market Size (2021-2032)
- 11.2 Middle East & Africa Preclinical Pharmacokinetics Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Preclinical Pharmacokinetics Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Preclinical Pharmacokinetics Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Porsolt
- 12.1.1 Porsolt Company Information
- 12.1.2 Porsolt Business Overview
- 12.1.3 Porsolt Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.1.4 Porsolt Preclinical Pharmacokinetics Services Product Portfolio
- 12.1.5 Porsolt Recent Developments
- 12.2 Altasciences
- 12.2.1 Altasciences Company Information
- 12.2.2 Altasciences Business Overview
- 12.2.3 Altasciences Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.2.4 Altasciences Preclinical Pharmacokinetics Services Product Portfolio
- 12.2.5 Altasciences Recent Developments
- 12.3 Biocytogen
- 12.3.1 Biocytogen Company Information
- 12.3.2 Biocytogen Business Overview
- 12.3.3 Biocytogen Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.3.4 Biocytogen Preclinical Pharmacokinetics Services Product Portfolio
- 12.3.5 Biocytogen Recent Developments
- 12.4 Charles River Laboratories
- 12.4.1 Charles River Laboratories Company Information
- 12.4.2 Charles River Laboratories Business Overview
- 12.4.3 Charles River Laboratories Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.4.4 Charles River Laboratories Preclinical Pharmacokinetics Services Product Portfolio
- 12.4.5 Charles River Laboratories Recent Developments
- 12.5 WuXi AppTec
- 12.5.1 WuXi AppTec Company Information
- 12.5.2 WuXi AppTec Business Overview
- 12.5.3 WuXi AppTec Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.5.4 WuXi AppTec Preclinical Pharmacokinetics Services Product Portfolio
- 12.5.5 WuXi AppTec Recent Developments
- 12.6 PyschoGenics
- 12.6.1 PyschoGenics Company Information
- 12.6.2 PyschoGenics Business Overview
- 12.6.3 PyschoGenics Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.6.4 PyschoGenics Preclinical Pharmacokinetics Services Product Portfolio
- 12.6.5 PyschoGenics Recent Developments
- 12.7 Evotec (Cyprotex)
- 12.7.1 Evotec (Cyprotex) Company Information
- 12.7.2 Evotec (Cyprotex) Business Overview
- 12.7.3 Evotec (Cyprotex) Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.7.4 Evotec (Cyprotex) Preclinical Pharmacokinetics Services Product Portfolio
- 12.7.5 Evotec (Cyprotex) Recent Developments
- 12.8 QPS
- 12.8.1 QPS Company Information
- 12.8.2 QPS Business Overview
- 12.8.3 QPS Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.8.4 QPS Preclinical Pharmacokinetics Services Product Portfolio
- 12.8.5 QPS Recent Developments
- 12.9 Aurigene Pharmaceutical Services
- 12.9.1 Aurigene Pharmaceutical Services Company Information
- 12.9.2 Aurigene Pharmaceutical Services Business Overview
- 12.9.3 Aurigene Pharmaceutical Services Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.9.4 Aurigene Pharmaceutical Services Preclinical Pharmacokinetics Services Product Portfolio
- 12.9.5 Aurigene Pharmaceutical Services Recent Developments
- 12.10 Frontage Laboratories
- 12.10.1 Frontage Laboratories Company Information
- 12.10.2 Frontage Laboratories Business Overview
- 12.10.3 Frontage Laboratories Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.10.4 Frontage Laboratories Preclinical Pharmacokinetics Services Product Portfolio
- 12.10.5 Frontage Laboratories Recent Developments
- 12.11 Dalriada
- 12.11.1 Dalriada Company Information
- 12.11.2 Dalriada Business Overview
- 12.11.3 Dalriada Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.11.4 Dalriada Preclinical Pharmacokinetics Services Product Portfolio
- 12.11.5 Dalriada Recent Developments
- 12.12 Sygnature Discovery
- 12.12.1 Sygnature Discovery Company Information
- 12.12.2 Sygnature Discovery Business Overview
- 12.12.3 Sygnature Discovery Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.12.4 Sygnature Discovery Preclinical Pharmacokinetics Services Product Portfolio
- 12.12.5 Sygnature Discovery Recent Developments
- 12.13 Admescope
- 12.13.1 Admescope Company Information
- 12.13.2 Admescope Business Overview
- 12.13.3 Admescope Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.13.4 Admescope Preclinical Pharmacokinetics Services Product Portfolio
- 12.13.5 Admescope Recent Developments
- 12.14 Imavita
- 12.14.1 Imavita Company Information
- 12.14.2 Imavita Business Overview
- 12.14.3 Imavita Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.14.4 Imavita Preclinical Pharmacokinetics Services Product Portfolio
- 12.14.5 Imavita Recent Developments
- 12.15 IQVIA Laboratories
- 12.15.1 IQVIA Laboratories Company Information
- 12.15.2 IQVIA Laboratories Business Overview
- 12.15.3 IQVIA Laboratories Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.15.4 IQVIA Laboratories Preclinical Pharmacokinetics Services Product Portfolio
- 12.15.5 IQVIA Laboratories Recent Developments
- 12.16 Pharmaron
- 12.16.1 Pharmaron Company Information
- 12.16.2 Pharmaron Business Overview
- 12.16.3 Pharmaron Revenue in Preclinical Pharmacokinetics Services Business (2021-2026)
- 12.16.4 Pharmaron Preclinical Pharmacokinetics Services Product Portfolio
- 12.16.5 Pharmaron Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst